Current antibody-based therapies designed to prevent Aβ, tau, and α-syn accumulation in tau- and synucleinopathies also merit testing in HD (Valera and Masliah, 2013; Plotkin and Cashman, 2020). This evidence concerns the gene MAPT and synucleinopathy.